Nuvectis Pharma, Inc. NVCT Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Nuvectis Pharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvectis Pharma, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvectis Pharma, Inc.'s total liabilities & equity?
- Nuvectis Pharma, Inc. (NVCT) reported total liabilities & equity of $25.4M in Q1 2026.
- How has Nuvectis Pharma, Inc.'s total liabilities & equity changed year-over-year?
- Nuvectis Pharma, Inc.'s total liabilities & equity decreased by 15.8% year-over-year, from $30.15M to $25.4M.
- What is the long-term trend for Nuvectis Pharma, Inc.'s total liabilities & equity?
- Over 4 years (2021 to 2025), Nuvectis Pharma, Inc.'s total liabilities & equity has grown at a 47.7% compound annual growth rate (CAGR), from $6.66M to $31.71M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.